YEREVAN (CoinChapter.com) — Quantum BioPharma revealed its purchase of $1 million in Bitcoin and other cryptocurrencies on December 20. This decision is part of the company’s strategy to diversify its treasury and engage in cryptocurrency transactions. However, the announcement led to a 10% drop in its Nasdaq shares.
The company did not disclose which specific tokens were included in its cryptocurrency portfolio. In a statement, Quantum BioPharma said it is now equipped to receive financing and conduct transactions using cryptocurrency.
QNTM performance on the Nasdaq. Source: Google FinanceIncreasing Corporate Adoption of Bitcoin
Quantum BioPharma’s move reflects a growing trend of companies adopting Bitcoin and other cryptocurrencies as part of their treasury management strategies. In November, Jiva Technologies, a wellness-focused e-commerce company, invested $1 million in Bitcoin, citing its potential as an inflation hedge. Similarly, video-sharing platform Rumble allocated $20 million from its cash reserves to Bitcoin last month.
Another biopharmaceutical company, Hoth Therapeutics, also joined the trend by investing $1 million in Bitcoin in November. These investments highlight the increasing interest of non-crypto businesses in digital assets.
Cryptocurrency as a Hedge Against Inflation
The latest US Consumer Price Index (CPI) data indicates that inflation rose by 2.7% year-over-year in November 2024, compared to 2.6% in October. This marks the sharpest monthly increase in seven months. Companies are looking to Bitcoin as a potential hedge against such inflationary pressures, driving further interest in cryptocurrency treasury strategies.
US core inflation rate. Source: Trading EconomicsQuantum BioPharma’s Role in Biotech and Crypto Adoption
Quantum BioPharma operates in the biopharmaceutical sector, offering biotech solutions for treating neurodegenerative diseases, metabolic syndromes, and alcohol misuse disorders. Listed on the Nasdaq, Canadian Securities Exchange, and Frankfurt Stock Exchange, the company is part of a broader movement integrating cryptocurrencies into traditional industries.
By adopting cryptocurrency for treasury management and transactions, Quantum BioPharma reflects the increasing synergy between traditional industries and digital assets.
Push for Bitcoin in Corporate Treasuries
Meanwhile, organizations are encouraging major corporations to explore Bitcoin. The National Center for Public Policy Research, a think tank based in Washington, recently proposed that Microsoft and Amazon consider Bitcoin treasury strategies.
At Microsoft’s annual meeting on Dec. 10, shareholders voted against this proposal, with the company labeling it “unnecessary.” Amazon shareholders are set to discuss a similar resolution in April 2025. The think tank plans to continue advocating for Bitcoin adoption in corporate treasuries in 2025.
MicroStrategy Leads Bitcoin Holdings
Among corporations, MicroStrategy remains the largest Bitcoin holder, with 439,000 BTC as of December 2024. The company’s long-standing strategy of acquiring Bitcoin has influenced other firms, including Quantum BioPharma, to explore cryptocurrency as part of their treasury assets.
Quantum BioPharma’s $1 million investment in Bitcoin places it among a growing list of companies integrating digital assets into their financial strategies.
